Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

Fig. 3

Subjects* with rSBA titers ≥1:8 at 7–10 years after the primary vaccination with MenACWY-TT or MenACWY-PS

MenACWY meningococcal A, C, W, Y, PS polysaccharide, rSBA serum bactericidal antibody assay using baby rabbit complement, TT tetanus toxoid

*In the according-to-protocol cohort for persistence

Back to article page